Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936376 | 1.00 | RAB9A (0.42) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3933113 | 0.93 | RAB9A (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3933105 | 0.93 | RAB9A (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3934504 | 0.87 | MAOB (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3934502 | 0.87 | MAOB (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL5857033 | 0.87 | KMT2A (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3945060 | 0.87 | KMT2A (0.44) | RAB9AKMT2ANPC1MEN1NPSR1 | |
| SCHEMBL3939876 | 0.85 | ALK (0.49) | RAB9ANPC1TP53SMN1; SMN2HPGD | |
| SCHEMBL3939787 | 0.85 | ALK (0.49) | RAB9ANPC1TP53SMN1; SMN2HPGD | |
| SCHEMBL3935269 | 0.83 | RAB9A (0.43) | RAB9AKMT2ANPC1MEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | claimed |
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | claimed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | RAB9A 3709/4885KMT2A 1839/4885NPC1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.